Guggenheim Capital LLC Fate Therapeutics Inc Transaction History

Guggenheim Capital LLC

  • $14 Billion
  • Q3 2024

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
SELL
$2.02 - $5.04 $71,279 - $177,846
-35,287 Reduced 62.06%
21,572 $45,000
Q2 2023

Aug 11, 2023
SELL
$4.76 - $6.59 $3,512 - $4,863
-738 Reduced 1.28%
56,859 $270,000
Q1 2023

May 10, 2023
SELL
$4.24 - $11.12 $268,476 - $704,118
-63,320 Reduced 52.37%
57,597 $328,000
Q4 2022

Feb 14, 2023
SELL
$9.86 - $23.83 $62,127 - $150,152
-6,301 Reduced 4.95%
120,917 $1.22 Million
Q3 2022

Nov 14, 2022
SELL
$21.04 - $36.06 $268,386 - $459,981
-12,756 Reduced 9.11%
127,218 $2.85 Million
Q2 2022

Aug 15, 2022
BUY
$17.78 - $42.39 $135,110 - $322,121
7,599 Added 5.74%
139,974 $3.47 Million
Q1 2022

May 16, 2022
SELL
$29.67 - $60.28 $727,300 - $1.48 Million
-24,513 Reduced 15.62%
132,375 $5.13 Million
Q4 2021

Feb 14, 2022
BUY
$47.84 - $64.34 $824,044 - $1.11 Million
17,225 Added 12.33%
156,888 $9.18 Million
Q3 2021

Nov 15, 2021
BUY
$59.27 - $95.73 $2.1 Million - $3.4 Million
35,489 Added 34.07%
139,663 $8.28 Million
Q2 2021

Aug 13, 2021
SELL
$67.25 - $92.52 $118,091 - $162,465
-1,756 Reduced 1.66%
104,174 $9.04 Million
Q1 2021

May 13, 2021
BUY
$72.16 - $117.4 $975,747 - $1.59 Million
13,522 Added 14.63%
105,930 $8.73 Million
Q4 2020

Feb 16, 2021
BUY
$38.09 - $100.95 $1.3 Million - $3.44 Million
34,100 Added 58.48%
92,408 $8.4 Million
Q3 2020

Nov 13, 2020
SELL
$30.41 - $40.5 $7,602 - $10,125
-250 Reduced 0.43%
58,308 $2.33 Million
Q2 2020

Aug 14, 2020
BUY
$20.21 - $35.23 $498,984 - $869,828
24,690 Added 72.9%
58,558 $2.01 Million
Q1 2020

Jun 02, 2020
BUY
$17.28 - $31.88 $240,243 - $443,227
13,903 Added 69.64%
33,868 $752,000
Q4 2019

Feb 14, 2020
BUY
$13.39 - $20.73 $97,907 - $151,577
7,312 Added 57.79%
19,965 $391,000
Q3 2019

Nov 14, 2019
BUY
$15.47 - $22.5 $195,741 - $284,692
12,653 New
12,653 $197,000
Q4 2017

Feb 14, 2018
SELL
$3.94 - $6.64 $41,905 - $70,623
-10,636 Closed
0 $0
Q3 2017

Nov 14, 2017
BUY
$2.6 - $4.31 $27,653 - $45,841
10,636
10,636 $43,000

Others Institutions Holding FATE

# of Institutions
175
Shares Held
115M
Call Options Held
53.7K
Put Options Held
9K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $260M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Guggenheim Capital LLC Portfolio

Follow Guggenheim Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email